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Abstract
The biologic basis of the negative prognosis of plasmablastic my-
eloma is not fully understood. To determine whether histologically
aggressive multiple myeloma (MM) is associated with a more angio-
genic marrow environment, bone marrow samples from 50 recently
diagnosed MM patients were evaluated. Twelve percent (6/50) of
patients presented plasmablastic MM, and this feature correlated with
moderate/strong intensity of vascular endothelial growth factor stain-
ing of plasma cells (P = 0.036). Although plasmablastic MM was not
associated with increasing of microvessel density, this new evidence
of increased expression of vascular endothelial growth factor on
plasmablasts suggests that the adverse prognosis conferred by plasma-
blastic disease may be due, at least in part, to secretion of this
angiogenic cytokine, also suggesting that the subset of MM patients
with plasmablastic features may derive particular benefit from
antiangiogenic therapies.
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Introduction
The amount of microvessels in the bone
marrow progressively increases along the
spectrum of plasma cell disorders and be-
comes a prominent feature in active multiple
myeloma (MM) (1). Some studies have es-
tablished that MM patients with increased
marrow angiogenesis have shorter overall
survival (2,3). Vascular endothelial growth
factor (VEGF) is one of the most important
angiogenic cytokines mediating tumor an-
giogenesis (4); assessed by immunohisto-
chemical methods, it has been detected in
plasma cells and plasmacytoma samples from
most MM patients (5,6).
Based on the hypothesis that the adverse
clinical evolution associated with plasma-
blastic MM (7,8) could be determined by an
increase of angiogenesis, we studied the cor-
relation between plasmablastic morphology,
microvessel density (MVD) and VEGF im-
munoexpression in the bone marrow samples
of 50 newly diagnosed MM patients. If this
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hypothesis were correct, this subset of MM
patients would be particularly suitable for
antiangiogenic therapies.
Material and Methods
Patients
We studied bone marrow samples from
fifty recently diagnosed MM patients, fol-
lowed at the Multiple Myeloma Outpatient
Service of the Discipline of Hematology and
Hemotherapy, UNIFESP/EPM, São Paulo,
SP, Brazil, between May 2000 and Decem-
ber 2002. Formalin-fixed, paraffin-embed-
ded bone marrow sections from 49 patients
were available, and 46 patients had also
assessable bone marrow smears. Written in-
formed consent was obtained from all pa-
tients and the institution’s Ethics Committee
approved the study.
Assessment of morphologic features
Marrow smears were stained with May-
Grünwald-Giemsa solution to evaluate
plasma cell number and morphology. Bone
marrow sections were studied after staining
with hematoxylin and eosin, Giemsa and
PAS. The disease was classified as plasma-
blastic or non-plasmablastic according to
the classification system of Bartl et al. (9),
and the percentage of infiltrating plasma
cells (tumor burden) was recorded.
Immunohistochemical studies
Immunohistochemical reactions were
performed using the streptavidin-biotin-per-
oxidase method and the following mono-
clonal antibodies: anti-kappa light chain
(1:5000; Dako, Carpinteria, CA, USA), anti-
lambda light chain (1:5000; Dako), anti-
CD34 (1:50; Dako), and anti-VEGF (1:100;
Santa Cruz Biotechnology, Santa Cruz, CA,
USA). The LSAB detection kit (Dako) was
used for antigen visualization. Paraffin sec-
tions of placental tissue were included in
each batch as positive control for CD34
immunohistochemical staining and sections
processed with exclusion of the primary an-
tibody were used as negative control. Sec-
tions were counterstained with hematoxylin
and examined by light microscopy.
Quantification of microvessels in bone
marrow
Angiogenesis was measured by counting
the CD34-labeled intratumoral microvessels
(MVD) (1), and the patients were stratified
into high-angiogenesis (MVD ≥20) and low-
angiogenesis status (MVD <20) according
to a previous study (10). To estimate the
MVD, the entire slide was scanned at 100X
magnification to locate three areas of maxi-
mum microvessels (hot spots) in which the
microvessels were counted at 400X. The
MVD was reported as the average number of
vessels in the three hot spots (1).
Assessment of VEGF expression
Cases were considered to be positive
when ≥10% of plasma cells showed the typi-
cal pattern of VEGF expression, evidenced
by diffuse cytoplasmic brown staining of
variable intensity among individual patients.
For the positive cases, VEGF immunoreac-
tivity was examined on the basis of staining
intensity (weak and moderate/strong). Given
the known VEGF expression by marrow
myelo-monocytic and megakaryocytic cells,
which invariably showed strong VEGF stain-
ing, these cells were used as positive internal
controls (4,5).
Statistical analysis
Associations between nominal variables
were tested by the Pearson chi-square test
(χ2) or by the Fisher exact test, with the level
of significance set at 5%. Statistical analysis
was performed using the SPSS 8.0 software.
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Results
The clinical characteristics of the pa-
tients are summarized in Table 1.
Histological characteristics
Bone marrow biopsies were available for
49 patients. Plasma cell infiltration in mar-
row samples ranged from 20 to 100% (me-
dian 80%). According to the classification
of Bartl et al. (9), 6 patients (12%) presented
plasmablastic disease, while 43 (88%) did
not (Figure 1).
Bone marrow angiogenesis
Forty-eight CD34-stained marrow sec-
tions were available to assess angiogenesis.
Median MVD was 25 microvessels per 400
high-power field (range: 3-130). Low angio-
genesis (MVD <20) was present in 13 (27%)
patients, and high angiogenesis (MVD ≥20)
was present in 35 patients (73%).
VEGF expression
Forty-nine sections were assessable for
VEGF analysis. Fourteen (29%) patients
showed VEGF expression in <10% positive
plasma cells (negative cases), while 35 (71%)
showed VEGF expression in ≥10% positive
plasma cells. Among the positive cases, 17
Table 1. Clinical characteristics of the 50 patients
studied.
Patients’ baseline characteristics N
Age (years)
Median 57
Range 28-83
Gender
Male 29 (58%)
Female 21 (42%)
Salmon-Durie stage
IIa 2 (4%)
IIb 1 (2%)
IIIa 19 (38%)
IIIb 28 (56%)
Isotype
IgG 24 (48%)
IgA 10 (20%)
IgM 1 (2%)
Not IgM, IgA, IgG 12 (24%)
Data missing  3 (6%)
Light chain
Kappa 27 (54%)
Lambda 18 (36%)
Not available 5 (10%)
(49%) displayed a weak intensity signal, while
18 (51%) showed moderate/strong intensity.
Correlations between morphologic feature,
VEGF expression and bone marrow
angiogenesis
Plasmablastic morphology did not show
an association with tumor burden in bone
Figure 1. Micrographs showing
plasmablasts in marrow smears
(A), plasmablasts in a marrow
biopsy (B), and plasmablasts
with strong vascular endothelial
growth factor immunostaining in
a marrow biopsy (C). Original
magnification, 400X.
A B C
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marrow biopsies (P = 0.614); also, there was
no association with angiogenesis status, as
assessed by MVD (P = 0.713). However,
plasmablastic MM significantly correlated
with moderate/strong VEGF intensity (P =
0.036; Table 2).
Discussion
Plasmablastic morphology is a well-rec-
ognized adverse morphologic feature in MM
(7,8). Findings from clinical and laboratory
studies have suggested that angiogenesis
takes part in the pathogenesis of MM (11),
and some studies have revealed angiogene-
sis as a prognostic factor for disease-related
survival and as a significant predictor of
plasmacytoma progression to MM (2,3).
The goal of this study was to investigate
the potential links between plasmablastic
morphology and angiogenesis in a series of
advanced, recently diagnosed MM patients,
hypothesizing that a histologically aggres-
sive disease would also correspond to a more
angiogenic bone marrow environment. As-
sessing VEGF immunoexpression in mar-
row biopsies in terms of staining intensity,
we arbitrarily set ≥10% of positive plasma
cells as the cut-off for considering a case as
positive.
Bellamy et al. (4) studied the VEGF
mRNA and protein expression in 12 human
hematopoietic tumor cell lines and in 16
MM patients. VEGF expression was defined
according to the intensity of cytoplasmic
staining; immunohistochemical analysis was
performed on formalin-fixed, paraffin-em-
bedded bone marrow clots or cores, and
plasma cell expression of VEGF was ob-
served in 12 of 16 patients, presenting as
diffuse cytoplasmic staining of variable in-
tensity among individual patients. With an
expanded cohort of 42 MM patients, using
the same immunohistochemistry method,
Bellamy (5) was able to observe plasma cell
expression of VEGF in the bone marrow of
33 (78%) patients.
We found an interesting association be-
tween plasmablastic morphology and mod-
erate/strong VEGF intensity even though we
did not detect a correlation between plasma-
blastic morphology and angiogenesis status.
This finding, although limited by the small
number of patients with plasmablastic fea-
tures, suggests that a histologically more
aggressive disease may be associated with
intensified production of VEGF. Although
VEGF expression has been significantly as-
sociated with immature morphology in plas-
macytomas (6), the correlation in MM has
not been previously reported.
Rajkumar et al. (1) analyzed angiogene-
sis in 400 patients with plasma cell dyscrasias
regarding medullary microvessels identified
by immunohistochemical staining for CD34.
From the relatively benign monoclonal gam-
mopathy of undetermined significance to
relapsed MM, the median MVD increased
significantly and high-grade angiogenesis
found to be progressively more frequent,
suggesting that angiogenesis may be related
to disease progression.
The high-angiogenesis status shared by
73% of our patients probably reflects the
virtually homogenous group of stage III dis-
Table 2. Correlation between the classification of Bartl et al. (9) and vascular endothe-
lial growth factor intensity and microvessel density in multiple myeloma patients.
Bartl’s classification Plasmablastic Non-plasmablastic
(N) (N)
PC BM (%)
<80% 2 (33%) 10 (24%)
≥80% 4 (67%) 32 (76%)
VEGF intensity*
Negative 0 14 (33%)
Weak 1 (17%) 16 (37%)
Moderate/strong 5 (83%) 13 (30%)
Angiogenesis status
Low (MVD <20) 2 (33%) 11 (26%)
High (MVD ≥20) 4 (67%) 31 (74%)
PC BM = plasma cells in bone marrow (median 80); VEGF = vascular endothelial
growth factor; MVD = microvessel density.
*Plasmablastic multiple myeloma significantly correlated with moderate/strong VEGF
intensity (P = 0.036)
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ease, highlighting the association of angio-
genesis with advanced MM. Although we
did not detect an association between plasma
cell percentage and MVD or VEGF, the hot
spots were generally found to be closely
related to focal areas of tumor infiltration
(data not shown), suggesting that autocrine
production of angiogenic cytokines was tak-
ing place.
In short, our findings suggest that plas-
mablastic MM is associated with increased
production of VEGF and confirm the asso-
ciation of advanced MM with increased an-
giogenesis. In view of current efforts to study
antiangiogenic drugs in the treatment of MM
(12), we believe that this subset of MM
patients could benefit from these therapies.
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